Cure My Disease

Don't miss your cure!

 Log in / Sign up

A baby wrap that fights malaria? a new trial puts treated fabric to the test

NCT ID NCT07773350

Prevention Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether baby wraps (called lesus) treated with long-lasting insecticide can protect young children from malaria. About 1,300 mothers and their infants (2-4 months old) will be randomly assigned to receive a wrap treated with permethrin, etofenprox, or an untreated wrap. Researchers will compare how many children in each group develop malaria to see if the treated wraps offer extra protection beyond standard prevention methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Permethrin-treated or etofenprox-treated lesu (baby wrap)
What this could lead to
If effective, these treated wraps could offer a simple, low-cost way to protect infants from malaria, reducing illness and death in high-risk areas.
What could go wrong
The trial is large but still experimental; the treated fabric may not reduce malaria enough to be practical, and there is a small risk of skin irritation or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,296 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 months to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mother is at least 18 years old * Mother has access to a working phone with a known number * Mother is the parent or legal guardian of a singleton (i.e., not a twin) infant 2-4 months of age * Has the ability to travel to a designated study site for visits and evaluation * Mother/Infant pair presents to their 10-week immunization visit at one of the designated study sites Exclusion Criteria: * Participation in another study of malaria prevention * Known allergic reaction to permethrin or etofenprox * Infant has a known HIV diagnosis (or exposure) or sickle cell disease that would be an indication for malaria prophylaxis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria (plasmodium falciparum) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria (plasmodium falciparum) Malaria incidence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mbarara University of Science and Technology

    Mbarara, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.